Rocket Pharmaceuticals, Inc.
RCKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $34,068 | $42,658 | $35,942 | $37,357 |
| G&A Expenses | $18,351 | $25,020 | $28,446 | $25,337 |
| SG&A Expenses | $18,351 | $25,020 | $28,446 | $25,337 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$172 | $3,471 | $0 | $0 |
| Operating Expenses | $52,247 | $71,149 | $64,388 | $62,694 |
| Operating Income | -$52,247 | -$71,149 | -$64,388 | -$62,694 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,915 | $2,230 | $3,054 | $2,367 |
| Pre-Tax Income | -$50,332 | -$68,919 | -$61,334 | -$60,327 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$50,332 | -$68,919 | -$61,334 | -$60,327 |
| % Margin | – | – | – | – |
| EPS | -0.45 | -0.62 | -0.56 | -0.62 |
| % Growth | 27.4% | -10.7% | 9.7% | – |
| EPS Diluted | -0.45 | -0.62 | -0.56 | -0.62 |
| Weighted Avg Shares Out | 111,571 | 111,020 | 110,093 | 97,530 |
| Weighted Avg Shares Out Dil | 111,571 | 111,020 | 110,093 | 97,530 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2,703 | $3,526 | $2,840 |
| Interest Expense | $473 | $473 | $472 | $473 |
| Depreciation & Amortization | $3,240 | $2,579 | $2,989 | $2,361 |
| EBITDA | -$46,619 | -$65,867 | -$57,873 | -$57,493 |
| % Margin | – | – | – | – |